FINDINGS SUPPORT THE HYPOTHESIS OF REDUCTIONS IN HEART ATTACKS AND STROKES
JOLIET, Ill., Oct. 19, 2016 /CNW/ -- Today, the prestigious American Journal of Medicine (The Green Journal) published the results of the study titled, "Randomized Trial of Plaque Identifying Toothpaste: Dental Plaque and Inflammation," which found that Plaque HD®, a plaque identifying toothpaste, significantly reduced dental plaque in the mouth and inflammation throughout the entire body.
In this study, 61 healthy subjects aged 19 to 44 years were randomized to Plaque HD® (n=31) or placebo (n=30) for 60 days. Changes from baseline to follow-up in dental plaque and hs-CRP were accessed:
- Plaque HD® significantly reduced dental plaque when compared with the placebo toothpaste
- Plaque HD® significantly reduced hs-CRP when compared with the placebo toothpaste
Inflammation is intimately involved in the pathogenesis of atherosclerosis and is accurately measured by high sensitivity C-reactive protein (hs-CRP), a sensitive marker for cardiovascular disease. Heart attack is the No. 1 cause of death in the world and the United States, killing over 370,000 men and women each year. Stroke is the No. 5 cause of death in the United States, killing nearly 129,000 men and women each year.1
The senior author was Charles H. Hennekens, M.D., Dr.P.H., who also authored the seminal article on inflammation, aspirin and heart disease published in 1997. In addition to conducting his groundbreaking research, Dr. Hennekens is the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, and the coauthors included investigators at the University of Illinois at Chicago School of Dentistry and the University of Wisconsin School of Medicine and Public Health. Last month, the prestigious New England Journal of Medicine noted that his 1997 study, "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men," was their most influential over the last 20 years. That original research from the landmark Physician's Health Study, in which Dr. Hennekens was founding Principal Investigator, was the first to demonstrate that C-reactive protein, a sensitive marker of inflammation, predicted future heart attacks and strokes.
Dr. Hennekens stated, "The observed reduction in inflammation among those assigned at random to Plaque HD® supports the hypothesis of a reduction in risks of heart attacks and strokes."
The Editor-in-Chief of the American Journal of Medicine, Joseph Alpert MD, a renowned cardiologist, took the unusual step to write an accompanying editorial: "Can a toothpaste reduce risks of heart attacks and strokes?" He opined about the relationship of oral health to heart attacks and strokes which he first learned from his father, a dentist.
"I am pleased and inspired by these results which suggest that the use of Plaque HD® can help reduce the risk of heart attacks and strokes," commented Lawrence Hier, DDS, MS, the CEO of TJA Health LLC and inventor of Plaque HD®. "Plaque is dangerous and an enemy of dental and overall health. Dental plaque has long been suspected to be a contributor to heart attacks and strokes."
Plaque HD® is the first plaque-identifying toothpaste that reveals plaque so that it can be removed with directed brushing. In addition, the product's proprietary formulation, Targetol Technology®, contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject more effectively remove the plaque.
"The direct test of the hypothesis that Plaque HD® reduces risks of heart attacks and strokes requires a large scale randomized trial of sufficient size and duration designed a priori to do so," stated Dr. Hennekens. "We are already preparing an investigator initiated research grant proposal to the United States National Institutes of Health (NIH) with coauthor Patrick McBride, MD, MPH, Professor of Medicine and Senior Associate Dean at the University of Wisconsin School of Medicine and Public Health as Principal Investigator."
Dr. Hennekens added, "This trial is important and timely because a positive finding would have enormous clinical and public health implications."
For more information about Plaque HD®, patients can visit www.plaquehd.com, and providers can visit www.plaquehdpro.com.
ABOUT Plaque HD®: Plaque HD® is the first professional plaque-identifying toothpaste. Plaque HD® uses Targetol® Technology to highlight the plaque missed while brushing, giving you that fresh-from-the-dentist feeling every day. With regular brushing, the 1-step, easy-to-use Plaque HD® formula fights cavities, freshens breath, and helps prevent gum disease. By brushing daily with Plaque HD® toothpaste, in addition to improving your oral hygiene, you are also enhancing the health of your entire body since plaque in the mouth is closely linked to many systemic diseases, such as heart disease and stroke.
1American Heart Association "Heart Disease, Stroke and Research Statistics At-a-Glance." Available online at: https://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm_480086.pdf
Last accessed on October 7, 2016
Bratskeir & Company
Deanna Thorman / Anneka Ranpuria
firstname.lastname@example.org / email@example.com
Photo - http://photos.prnewswire.com/prnh/20161018/430061
Logo - http://photos.prnewswire.com/prnh/20161018/430060LOGO
SOURCE Plaque HD